FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207597418> ?p ?o ?g. }

• W3207597418 endingPage "931" @default.
• W3207597418 startingPage "921" @default.
• W3207597418 abstract "Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in haemophilia A or B patients with inhibitors (≥12 years of age). We describe here the EB safety profile from the three prospective Phase 3 clinical trials performed to date.To assess EB safety, immunogenicity and thrombotic potential in children and adults who received EB for treatment of bleeding and perioperative care.Using a randomized crossover design, 27 subjects in PERSEPT 1 (12-54 years) and 25 subjects in PERSEPT 2 (1-11 years) treated bleeding episodes with 75 or 225 μg/kg EB initially followed by 75 μg/kg dosing at predefined intervals as determined by clinical response. Twelve PERSEPT 3 subjects (2-56 years) received an initial preoperative infusion of 75 μg/kg (minor procedures) or 200 μg/kg EB (major surgeries) with subsequent 75 μg/kg doses administered intraoperatively and post-operatively as indicated. Descriptive statistics were used for data analyses.Sixty subjects who received 3388 EB doses in three trials were evaluated. EB was well tolerated, with no allergic, hypersensitivity, anaphylactic or thrombotic events reported and no neutralizing anti-EB antibodies detected. A death occurred during PERSEPT 3 and was determined to be unlikely related to EB treatment by the data monitoring committee.Results from all three Phase 3 trials establish an excellent safety profile of EB in haemophilia A or B patients with inhibitors for treatment of bleeding and perioperative use." @default.
• W3207597418 created "2021-10-25" @default.
• W3207597418 creator A5000917771 @default.
• W3207597418 creator A5001170166 @default.
• W3207597418 creator A5004021370 @default.
• W3207597418 creator A5004338432 @default.
• W3207597418 creator A5006881585 @default.
• W3207597418 creator A5008435049 @default.
• W3207597418 creator A5010852837 @default.
• W3207597418 creator A5017113740 @default.
• W3207597418 creator A5018280451 @default.
• W3207597418 creator A5032393853 @default.
• W3207597418 creator A5038396248 @default.
• W3207597418 creator A5038597185 @default.
• W3207597418 creator A5043838316 @default.
• W3207597418 creator A5047186264 @default.
• W3207597418 creator A5048998886 @default.
• W3207597418 creator A5066096990 @default.
• W3207597418 creator A5071048526 @default.
• W3207597418 creator A5072267313 @default.
• W3207597418 creator A5072973093 @default.
• W3207597418 creator A5073241613 @default.
• W3207597418 creator A5074654320 @default.
• W3207597418 creator A5076531502 @default.
• W3207597418 creator A5079219637 @default.
• W3207597418 creator A5079380427 @default.
• W3207597418 creator A5080646091 @default.
• W3207597418 creator A5084393420 @default.
• W3207597418 creator A5084750013 @default.
• W3207597418 creator A5087701839 @default.
• W3207597418 creator A5090627517 @default.
• W3207597418 creator A5090963710 @default.
• W3207597418 date "2021-10-11" @default.
• W3207597418 modified "2023-10-14" @default.
• W3207597418 title "The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors" @default.
• W3207597418 cites W1514947270 @default.
• W3207597418 cites W1794693816 @default.
• W3207597418 cites W1954616286 @default.
• W3207597418 cites W1983707924 @default.
• W3207597418 cites W1998000461 @default.
• W3207597418 cites W2018329327 @default.
• W3207597418 cites W2046936517 @default.
• W3207597418 cites W2047720977 @default.
• W3207597418 cites W2073584790 @default.
• W3207597418 cites W2087131972 @default.
• W3207597418 cites W2087677741 @default.
• W3207597418 cites W2090723639 @default.
• W3207597418 cites W2098951552 @default.
• W3207597418 cites W2106722871 @default.
• W3207597418 cites W2110815781 @default.
• W3207597418 cites W2111674410 @default.
• W3207597418 cites W2117437723 @default.
• W3207597418 cites W2148505112 @default.
• W3207597418 cites W2150269473 @default.
• W3207597418 cites W2170623254 @default.
• W3207597418 cites W2402278381 @default.
• W3207597418 cites W2510646213 @default.
• W3207597418 cites W2564321165 @default.
• W3207597418 cites W2624639915 @default.
• W3207597418 cites W2731588942 @default.
• W3207597418 cites W2734287351 @default.
• W3207597418 cites W2744114002 @default.
• W3207597418 cites W2763688680 @default.
• W3207597418 cites W2884860360 @default.
• W3207597418 cites W2892811509 @default.
• W3207597418 cites W2900118404 @default.
• W3207597418 cites W2901613838 @default.
• W3207597418 cites W2905598595 @default.
• W3207597418 cites W2945243639 @default.
• W3207597418 cites W2971410759 @default.
• W3207597418 cites W3000359647 @default.
• W3207597418 cites W3207597418 @default.
• W3207597418 cites W4292528167 @default.
• W3207597418 doi "https://doi.org/10.1111/hae.14419" @default.
• W3207597418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34636112" @default.
• W3207597418 hasPublicationYear "2021" @default.
• W3207597418 type Work @default.
• W3207597418 sameAs 3207597418 @default.
• W3207597418 citedByCount "6" @default.
• W3207597418 countsByYear W32075974182021 @default.
• W3207597418 countsByYear W32075974182022 @default.
• W3207597418 countsByYear W32075974182023 @default.
• W3207597418 crossrefType "journal-article" @default.
• W3207597418 hasAuthorship W3207597418A5000917771 @default.
• W3207597418 hasAuthorship W3207597418A5001170166 @default.
• W3207597418 hasAuthorship W3207597418A5004021370 @default.
• W3207597418 hasAuthorship W3207597418A5004338432 @default.
• W3207597418 hasAuthorship W3207597418A5006881585 @default.
• W3207597418 hasAuthorship W3207597418A5008435049 @default.
• W3207597418 hasAuthorship W3207597418A5010852837 @default.
• W3207597418 hasAuthorship W3207597418A5017113740 @default.
• W3207597418 hasAuthorship W3207597418A5018280451 @default.
• W3207597418 hasAuthorship W3207597418A5032393853 @default.
• W3207597418 hasAuthorship W3207597418A5038396248 @default.
• W3207597418 hasAuthorship W3207597418A5038597185 @default.
• W3207597418 hasAuthorship W3207597418A5043838316 @default.
• W3207597418 hasAuthorship W3207597418A5047186264 @default.
• W3207597418 hasAuthorship W3207597418A5048998886 @default.

• next